CLRB Stock UPDATES Cellectar Biosciences Inc. (CLRB) 3.00 09/10/2014
Post# of 273256
Posted On: 09/10/2014 7:06:10 PM
Cellectar Biosciences Inc. (CLRB) 3.00 $CLRB
Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September
GlobeNewswire - Fri Sep 05, 8:46AM CDT
Rodman & Renshaw 16 Annual Global Investment Conference on September 9, 2014
Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed or refractory multiple myeloma, an incurable cancer of plasma cells.
Cellectar Biosciences Reports Second Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Aug 20, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the second quarter 2014.
Cellectar Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option
GlobeNewswire - Wed Aug 20, 3:13PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced the closing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants have an exercise price of $4.68 per share, are immediately exercisable and expire in August 2019.
Cellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress
GlobeNewswire - Mon Aug 18, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss second quarter 2014 financial results and provide an update on each of its development programs on Wednesday, August 20th at 5:00 PM ET.
Cellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital Market
GlobeNewswire - Thu Aug 14, 6:40PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced today the pricing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants are exercisable immediately and expire five years from their date of issuance. The warrants will have an exercise price of $4.68 per share and will trade on the NASDAQ Capital Market under the symbol "CLRBW."
Cellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed/refractory multiple myeloma, an incurable cancer of plasma cells.
Cellectar Biosciences Announces 1-for-20 Reverse Stock Split and Reduction in Authorized Shares of Common Stock
GlobeNewswire - Fri Jun 13, 7:29AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), announced a 1-for-20 reverse stock split of its common stock, effective at the close of business today, as a first step in a planned listing of its common stock on the NASDAQ Capital Market.
Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and CEO of Cellectar as planned following six months as acting chief executive officer. Dr. Pedder will continue to serve as a director.
Cellectar Biosciences Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the year ended December 31, 2013.
Cellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress
GlobeNewswire - Wed Mar 19, 7:54AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss full year 2013 financial results, provide an update on each of its development programs and discuss expectations for fiscal 2014 on Tuesday, March 25 at 5:00 PM ET.
Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
GlobeNewswire - Tue Mar 04, 7:01AM CST
Cellectar Biosciences, Inc. (OTCQX:CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the first patient in its Phase II imaging trial of I-124-CLR1404 in patients with glioblastoma.
Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September
GlobeNewswire - Fri Sep 05, 8:46AM CDT
Rodman & Renshaw 16 Annual Global Investment Conference on September 9, 2014
Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed or refractory multiple myeloma, an incurable cancer of plasma cells.
Cellectar Biosciences Reports Second Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Aug 20, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the second quarter 2014.
Cellectar Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option
GlobeNewswire - Wed Aug 20, 3:13PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced the closing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants have an exercise price of $4.68 per share, are immediately exercisable and expire in August 2019.
Cellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress
GlobeNewswire - Mon Aug 18, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss second quarter 2014 financial results and provide an update on each of its development programs on Wednesday, August 20th at 5:00 PM ET.
Cellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital Market
GlobeNewswire - Thu Aug 14, 6:40PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced today the pricing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants are exercisable immediately and expire five years from their date of issuance. The warrants will have an exercise price of $4.68 per share and will trade on the NASDAQ Capital Market under the symbol "CLRBW."
Cellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed/refractory multiple myeloma, an incurable cancer of plasma cells.
Cellectar Biosciences Announces 1-for-20 Reverse Stock Split and Reduction in Authorized Shares of Common Stock
GlobeNewswire - Fri Jun 13, 7:29AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), announced a 1-for-20 reverse stock split of its common stock, effective at the close of business today, as a first step in a planned listing of its common stock on the NASDAQ Capital Market.
Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and CEO of Cellectar as planned following six months as acting chief executive officer. Dr. Pedder will continue to serve as a director.
Cellectar Biosciences Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the year ended December 31, 2013.
Cellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress
GlobeNewswire - Wed Mar 19, 7:54AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss full year 2013 financial results, provide an update on each of its development programs and discuss expectations for fiscal 2014 on Tuesday, March 25 at 5:00 PM ET.
Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
GlobeNewswire - Tue Mar 04, 7:01AM CST
Cellectar Biosciences, Inc. (OTCQX:CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the first patient in its Phase II imaging trial of I-124-CLR1404 in patients with glioblastoma.
(0)
(0)Scroll down for more posts ▼